Influence of CD26 and integrins on the antigen sensitivity of human memory T cells

Human Immunology

Volumn 50, Issue 2, 1996, Pages 79-90

  Falcioni, Fiorensa ^a   Shah, Himanshu ^a   Vidović, Damir ^a   Morimoto, Chikao ^b   Belunis, Charles ^a   Bolin, David ^a   Nagy, Zoltan A ^a  

^a HOFFMANN LA ROCHE INC   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; INTEGRIN;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; HUMAN; HUMAN CELL; LYMPHOCYTE CLONE; LYMPHOCYTE PROLIFERATION; MEMORY CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0030271995     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/0198-8859(96)00121-8     Document Type: Article

References (46)

1. 1. Bierer BE, Sleckman BP, Ratnofsky SE, Burakoff SJ: The biological roles of CD2, CD4, and CD8 in T-cell activation. Annu Rev Immunol 7:579, 1989.
2. 2. Larson RS, Springer TA: Structure and function of leukocyte integrins. Immunol Rev 114:181, 1990.
3. 3. Mueller DL, Jenkins MK, Schwartz RH: Clonal expansion versus functional inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 7:445, 1989.
4. 4. Böhmig GA, Kovarik J, Holter W, Pohanka E, Zlabinger GJ: Specific down-regulation of proliferative T cell alloresponsiveness by interference with CD2/LFA-3 and LFA-1/ICAM-1 in vitro. J Immunol 152:3720, 1994.
5. 5. Emmrich F, Strittmatter U, Eichman K: Synergism in the activation of human CD8 T cells by cross-linking the T-cell receptor complex with the CD8 differentiation antigen. Proc Natl Acad Sci USA 83:8298, 1986.
6. 6. Anderson P, Blue M-L, Morimoto C, Schlossman SF: Cross-linking of T3 (CD3) with T4 (CD4) enhances the proliferation of resting T lymphocytes. J Immunol 139: 678, 1987.
7. 7. Dang NH, Torimoto Y, Deusch K, Schlossman SF, Morimoto: Comitogenic effect of solid-phase immobilized anti-1F7 on human CD4 T cell activation via CD3 and CD2 pathways. J Immunol 144:4092, 1990.
8. 8. Bednarczyk JL, Carroll SM, Marin C, McIntyre BW: Triggering of the proteinase dipeptidyl peptidase IV (CD26) amplifies human T lymphocyte proliferation. J Cell Biochem 46:206, 1991.
9. 9. Bockenstedt LK, Goldsmith MA, Dustin M, Oliver D, Springer TA, Weiss A: The CD2 ligand LFA-3 activates T cells but depends on the expression and function of the antigen receptor. J Immunol 141:1904, 1988.
10. 10. Van Seventer GA, Shimizu Y, Morgan KJ, Shaw S: The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 144:4579, 1990.
11. 11. Moingeon P, Chang H-C, Wallner BP, Stebbins C, Frey AZ, Reinherz EL: CD2-mediated adhesion facilitates T lymphocyte antigen recognition function. Nature 339: 312, 1989.
12. 12. Tanaka T, Duke-Cohan JS, Kameoka J, Yaron A, Lee I, Schlossman SF, Morimoto C: Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. Proc Natl Acad Sci USA 91:3082, 1994.
13. 13. Schön E, Jahn S, Kiessig ST, Demuth H-U, Neubert K, Barth A, Von Baehr R, Ansorge S: The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibitors and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation and immunoglobulin synthesis in vitro. Eur J Immunol 17:1821, 1987.
14. 14. Bierer BE, Peterson A, Gorga JC, Herrmann SH, Burakoff SJ: Synergistic T cell activation via the physiological ligands for CD2 and the T cell receptor. J Exp Med 168: 1145, 1988.
15. 15. Kuboto T, Flentke GR, Bachovchin WW, Stollar BD: Involvement of dipeptidyl peptidase IV in an in vivo immune response. Clin Exp Immunol 89:192, 1992.
16. 1 a novel 105 kD human T cell activation antigen defined by a monoclonal antibody. J Immunol 133:1250, 1984.
17. 17. Sanders ME, Makgoba MW, Sharrow SO, Stephany D, Springer TA, Young HA, Shaw S: Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29, and Pgp-1) and have enhanced IFN-γ production. J Immunol 140:1401, 1988.
18. 18. Morimoto C, Torimoto Y, Levinson G, Rudd CE, Schreiber M, Dang NH, Letvin NL, Schlossman SF: 1F7, a novel cell surface molecule involved in helper function of CD4 cells. J Immunol 143:3430, 1989.
19. 19. Hammer J, Takacs B, Sinigaglia F: Identification of a motif for HLA-DR1 binding peptides using M13 display libraries. J Exp Med 176:1007, 1992.
20. 20. Klohe EP, Watts R, Bahl M, Alber C, Yu W-Y, Anderson R, Silver J, Gregersen PK, Karr RW: Analysis, of the molecular specificities of anti-class II monoclonal antibodies by using L cell transfectants expressing HLA class II molecules. J Immunol 141:2158, 1988.
21. 21. Ishioka GY, Adorini L, Guery J-C, Gaeta FCA, LaFond R, Alexander J, Powell MF, Sette A, Grey HM: Failure to demonstrate long-lived MHC saturation both in vitro and in vivo. Implications for therapeutic potential of MHC-blocking peptides. J Immunol 152:4310, 1994.
22. 22. De Magistris MT, Alexander J, Coggeshall M, Altman A, Gaeta FCA, Grey HM, Sette A: Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 68:625, 1992.
23. 23. Harding CV, Unanue ER: Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T-cell stimulation. Nature 346:574, 1990.
24. 24. Demotz S, Grey HM, Sette A: The minimal number of class II MHC-antigen complexes needed for T cell activation. Science 249:1028, 1990.
25. 25. Christinick ER, Luscher MA, Barber BH, Williams DB: Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 352: 67, 1991.
26. 26. Valitutti S, Müller S, Celia M, Padovan E, Lanzavecchia A: Serial triggering of many T-cell receptors by few peptide-MHC complexes. Nature 375:148, 1995.
27. 27. Haynes BF, Telen MJ, Hale LP, Denning SM: CD44 - a molecule involved in leukocyte adherence and T-cell activation. Immunol Today 10:423, 1989.
28. 28. Smith SH, Brown MH, Rowe D, Callard RE, Beverly PCL: Functional subsets of human helper-inducer cells defined by a new monoclonal antibody, UCHL-1. Immunology 58:63, 1986.
29. 29. Torimoto Y, Dang NH, Tanaka T, Prado C, Schlossman SF, Morimoto C: Biochemical characterization of CD26 (dipeptidyl peptidase IV): functional comparison of distinct epitopes recognized by various anti-CD26 monoclonal antibodies. Cell Immunol 29:183, 1992.
30. 30. Evavold BD, Sloan-Lancaster J, Allen PM: Antagonism of superantigen-stimulated helper T-cell clones and hybridomas by altered peptide ligand. Proc Natl Acad Sci USA 91:2300, 1994.
31. 31. Bertoletti A, Sette A, Chisari FV, Penna A, Levrero M, De Carli M, Flaccadori F, Ferrari C: Natural variants of cytotoxic epitopes are T-cell receptor antagonists for anti-viral cytotoxic T cells. Nature 369:407, 1994.
32. 32. Hogguist KA, Jameson SC, Bevan MJ: Strong agonist ligands for the T cell receptor do not mediated positive selection of functional CD8+ T cells. Immunity 3:79, 1995.
33. 33. Alexander J, Snoke K, Ruppert J, Sidney J, Wall M, Southwood S, Oseroff C, Arrhenius T, Gaeta FCA, Colon SM, Grey HM, Sette A: Functional consequences of engagement of the T cell receptor by low affinity ligands. J Immunol 150:1, 1993.
34. 34. Dustin ML, Springer TA: T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 341:619, 1989.
35. 35. Hahn WC, Rosenstein Y, Clavo V, Burakoff SJ, Bierer B: A distinct cytoplasmic domain of CD2 regulates ligand avidity and T-cell responsiveness to antigen. Proc Natl Acad Sci USA 89:7179, 1992.
36. 36. O'Rourke AM, Rogers J, Mescher MF: Activated CD8 binding to class I protein mediated by the T-cell receptor results in signalling. Nature 346:187, 1991.
37. 37. Byrne JA, Butler JL, Cooper MD: Differential activation requirements for virgin and memory T cells. J Immunol 141:3249, 1988.
38. 38. Sanders ME, Makgoba MW, June CH, Young HA, Shaw S: Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor-mediated activation. Eur J Immunol 19:803, 1989.
39. 39. O'Sullivan D, Sidney J, Appella E, Walker L, Phillips L, Colon SM, Miles C, Chesnut RW, Sette A: Characterization of the specificity of peptide binding to four DR haplotypes. J Immunol 145:1799, 1990.
40. 40. Matsui K, Boniface JJ, Reay PA, Schild H, Fazekas de St. Growth B, Davis MM: Low affinity interaction of peptide-MHC complexes with T cell receptors. Science (Wash DC) 254:1788, 1991.
41. 41. Weber S, Traunecker A, Oliveri F, Gerhard W, Karjalainen K: Specific low-affinity recognition of major histocompatibility complex plus peptide by soluble T-cell receptor. Nature 356:793, 1992.
42. 42. Vidovic' D, Falcioni F, Bolin DR, Nagy ZA: Down-regulation of class II major histocompatibility complex molecules on antigen presenting cells after interaction with helper T cells. Eur J Immunol 25:1326, 1995.
43. 43. Gammon G, Shastri N, Cogswell J, Wilbur S, Sadegh-Nasseri S, Krzych U, Miller A, Sercarz EE: The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol Rev 98:53, 1987.
44. 44. Ashton-Rickardt PG, Bandeira A, Delaney JR, Van Kaer L, Pircher H-P, Zinkernagel RM, Tonegawa S: Evidence for a differential avidity model of T cell selection in the thymus. Cell 76:651, 1994.
45. 45. Adorini L, Nagy ZA: Inhibition of T cell activation by MHC blockade. Int Rev Immunol 6:23, 1990.
46. 46. Lehmann PV, Cardinaux F, Appella E, Muller S, Falcioni F, Adorini L, Nagy ZA: Inhibition of T cell response with peptides is influenced by both peptide-binding specificity of major histocompatibility complex molecules and susceptibility of T cells to blocking. Eur J Immunol 19: 1071, 1989.